Osimertinib has evidenced significant anti-cancer efficacy in lung cancer patients who are positive for T790M; in particular, PFS after acquired resistance to afatinib was longer than with 1st generation EGFR-TKI [7–10]. This evidence concerns the gene EGFR and lung carcinoma.